Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Total Debt (2020 - 2023)

C4 Therapeutics' Total Debt history spans 4 years, with the latest figure at $10.3 million for Q2 2023.

  • For Q2 2023, Total Debt fell 7.08% year-over-year to $10.3 million; the TTM value through Jun 2023 reached $10.3 million, down 7.08%, while the annual FY2022 figure was $11.5 million, 6.63% up from the prior year.
  • Total Debt reached $10.3 million in Q2 2023 per CCCC's latest filing, down from $10.9 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $11.5 million in Q4 2022 to a low of $9.9 million in Q3 2020.
  • Average Total Debt over 4 years is $10.7 million, with a median of $10.7 million recorded in 2021.
  • Peak YoY movement for Total Debt: increased 7.2% in 2021, then dropped 7.08% in 2023.
  • A 4-year view of Total Debt shows it stood at $10.1 million in 2020, then increased by 7.12% to $10.8 million in 2021, then grew by 6.63% to $11.5 million in 2022, then decreased by 9.99% to $10.3 million in 2023.
  • Per Business Quant, the three most recent readings for CCCC's Total Debt are $10.3 million (Q2 2023), $10.9 million (Q1 2023), and $11.5 million (Q4 2022).